Subjects

Abstract

Purpose

We conducted a consented pilot newborn screening (NBS) for Pompe, Gaucher, Niemann–Pick A/B, Fabry, and MPS 1 to assess the suitability of these lysosomal storage disorders (LSDs) for public health mandated screening.

Methods

At five participating high–birth rate, ethnically diverse New York City hospitals, recruiters discussed the study with postpartum parents and documented verbal consent. Screening on consented samples was performed using multiplexed tandem mass spectrometry. Screen-positive infants underwent confirmatory enzymology, DNA testing, and biomarker quantitation when available. Affected infants are being followed for clinical management and long-term outcome.

Results

Over 4 years, 65,605 infants participated, representing an overall consent rate of 73%. Sixty-nine infants were screen-positive. Twenty-three were confirmed true positives, all of whom were predicted to have late-onset phenotypes. Six of the 69 currently have undetermined disease status.

Conclusion

Our results suggest that NBS for LSDs is much more likely to detect individuals at risk for late-onset disease, similar to results from other NBS programs. This work has demonstrated the feasibility of using a novel consented pilot NBS study design that can be modified to include other disorders under consideration for public health implementation as a means to gather critical evidence for evidence-based NBS practices.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Wang RY, Bodamer OA, Watson MS, Wilcox WR, ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011;13:457–484.

  2. 2.

    Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis. 2004;27:385–410.

  3. 3.

    Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31–40.

  4. 4.

    Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122:e39–45.

  5. 5.

    Liao HC, Chiang CC, Niu DM, et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry—a national newborn screening program in Taiwan. Clin Chim Acta. 2014;431:80–86.

  6. 6.

    Chien YH, Lee NC, Huang HJ, et al. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr. 2011;158:1023–7e1.

  7. 7.

    Paciotti S, Persichetti E, Pagliardini S, et al. First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Clin Chim Acta. 2012;413:1827–1831.

  8. 8.

    Wittmann J, Karg E, Turi S, et al. Newborn screening for lysosomal storage disorders in Hungary. JIMD Rep. 2012;6:117–125.

  9. 9.

    Elliott S, Buroker N, Cournoyer JJ, et al. Pilot study of newborn screening for six lysosomal storage diseases using tandem mass spectrometry. Mol Genet Metab. 2016;118:304–309.

  10. 10.

    Burlina AB, Polo G, Salviati L, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41:209–219.

  11. 11.

    Botkin JR, Lewis MH, Watson MS, et al. Bioethics and Legal Work Group of the Newborn Screening Translational Research Network. Parental permission for pilot newborn screening research: guidelines from the NBSTRN. Pediatrics. 2014;133:e410–7.

  12. 12.

    Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001;47:1945–1955.

  13. 13.

    Comeau AM, Eaton RB, Successes of newborn screening programs. Science. 2002;295:44–45.

  14. 14.

    Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113:1573–1581.

  15. 15.

    Feuchtbaum L, Lorey F, Faulkner L, et al. California’s experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry. Pediatrics. 2006;117(5 pt 2):S261–9.

  16. 16.

    Orsini JJ, Martin MM, Showers AL, et al. Lysosomal storage disorder 4 + 1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders. Clin Chim Acta. 2012;413:1270–1273.

  17. 17.

    Elliott S, Buroker N, Cournoyer JJ, et al. Dataset and standard operating procedure for newborn screening of six lysosomal storage diseases: by tandem mass spectrometry. Data Brief. 2016;8:915–924.

  18. 18.

    Lin N, Huang J, Violante S, et al. Liquid chromatography-tandem mass spectrometry assay of leukocyte acid alpha-glucosidase for post-newborn screening evaluation of Pompe disease. Clin Chem. 2017;63:842–851.

  19. 19.

    Zhang XK, Elbin CS, Chuang WL, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem. 2008;54:1725–1728.

  20. 20.

    Li Y, Scott CR, Chamoles NA, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004;50:1785–1796.

  21. 21.

    Gelb MH, Turecek F, Scott CR, Chamoles NA, Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006;29:397–404.

  22. 22.

    Desnick RJ, Allen KY, Desnick SJ, et al. Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973;81:157–171.

  23. 23.

    Hsu TR, Hung SC, Chang FP, et al. Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol. 2016;68:2554–2563.

  24. 24.

    Lukas J, Scalia S, Eichler S, et al. Functional and clinical consequences of novel alpha-galactosidase A mutations in Fabry disease. Hum Mutat. 2016;37:43–51.

  25. 25.

    1000genomes. http://www.1000genomes.org, March 8, 2018.

  26. 26.

    Fost N. Informed consent should be a required element for newborn screening, even for disorders with high benefit-risk ratios. J Law Med Ethics. 2016;44:241–255.

  27. 27.

    Pass K, Green NS, Lorey F, et al. Pilot programs in newborn screening. Ment Retard Dev Disabil Res Rev. 2006;12:293–300.

  28. 28.

    Hopkins PV, Campbell C, Klug T, et al. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166:172–177.

  29. 29.

    Burton BK, Charrow J,Hoganson GE, et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;190:130–135.

  30. 30.

    Inoue T, Hattori K, Ihara K, et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58:548–552.

  31. 31.

    Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30:1397–1405.

  32. 32.

    Lenders M, Weidemann F, Kurschat C, et al. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11:54

  33. 33.

    Doheny D, Srinivasan R, Pagant S, et al. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018;55:261–268.

  34. 34.

    Ross LF, Saal HM, David KL, Anderson RR, American Academy of Pediatrics, American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet Med . 2013;15:234–245.

  35. 35.

    Botkin JR, Belmont JW, Berg JS, et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 2015;97:6–21.

  36. 36.

    Newborn Screening Translational Research Network. Longitudinal Pediatric Data Resource (LPDR). https://www.nbstrn.org/research-tools/longitudinal-pediatric-data-resource, January 12, 2018.

  37. 37.

    Hall PL, Marquardt G, McHugh DM, et al. Postanalytical tools improve performance of newborn screening by tandem mass spectrometry. Genet Med. 2014;16:889–895.

  38. 38.

    Marquardt G, Currier R, McHugh DM, et al. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med. 2012;14:648–655.

  39. 39.

    Mayo Clinic. Collaborative Laboratory Interpretive Reports. https://clir.mayo.edu, July 12, 2017.

  40. 40.

    Minter Baerg MM, Stoway SD, et al. Precision newborn screening for lysosomal disorders. Genet Med. 2017 November 9. [Epub ahead of print] https://doi.org/10.1038/gim.2017.194

Download references

Acknowledgements

Special thanks to Dalia Makarem, Aliza Quinones, Katherine Carome, Rebecca Zarchin, Tori Velez, Ryan Wilson, Chad Biski, and Christopher Johnson, and to Priya Kishnani and Deeksha Bali for their expert advice. Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R01HD073292. This research was facilitated by the Newborn Screening Translational Research Network (NBSTRN), which is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (HHSN275201300011C).

Author information

Affiliations

  1. Albert Einstein College of Medicine and the Children’s Hospital at Montefiore, Bronx, New York, USA

    • Melissa P. Wasserstein MD
    • , Nicole R. Kelly MPH
    •  & Suhas M. Nafday MD
  2. Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, New York, USA

    • Michele Caggana Sc.D.
    • , Monica Martin PhD
    •  & Joseph J. Orsini PhD
  3. New York University School of Medicine and NYU Langone Health, New York, New York, USA

    • Sean M. Bailey MD
  4. Icahn School of Medicine at Mount Sinai and the Mount Sinai Medical Center, New York, New York, USA

    • Robert J. Desnick PhD, MD
    • , Lisa Edelmann PhD
    • , Lissette Estrella NP
    • , Ian Holzman MD
    • , Ruth Kornreich PhD
    • , Amy Yang MD
    •  & Chunli Yu MD
  5. Maimonides Medical Center, Brooklyn, New York, USA

    • S. Gabriel Kupchik MD
  6. New York City Health and Hospitals/Elmhurst, Queens, New York, USA

    • Randi Wasserman MD

Authors

  1. Search for Melissa P. Wasserstein MD in:

  2. Search for Michele Caggana Sc.D. in:

  3. Search for Sean M. Bailey MD in:

  4. Search for Robert J. Desnick PhD, MD in:

  5. Search for Lisa Edelmann PhD in:

  6. Search for Lissette Estrella NP in:

  7. Search for Ian Holzman MD in:

  8. Search for Nicole R. Kelly MPH in:

  9. Search for Ruth Kornreich PhD in:

  10. Search for S. Gabriel Kupchik MD in:

  11. Search for Monica Martin PhD in:

  12. Search for Suhas M. Nafday MD in:

  13. Search for Randi Wasserman MD in:

  14. Search for Amy Yang MD in:

  15. Search for Chunli Yu MD in:

  16. Search for Joseph J. Orsini PhD in:

Disclosure

Melissa Wasserstein has served as a consultant for and has received travel reimbursement from Sanofi Genzyme. Robert J. Desnick is a consultant for Amicus Therapeutics, Sanofi Genzyme, and Sangamo Therapeutics. He has received research grants from Sanofi Genzyme and Sangamo Therapeutics. He owns founder's shares for Amicus Therapeutics and options for Sangamo Therapeutics. He has patents for Fabry and Niemann–Pick treatments and receives royalties from Sanofi Genzyme. Lisa Edelmann is an employee of Sema4, a for-profit genetic testing laboratory. Ruth Kornreich is an employee of Sema4, a for-profit genetic testing laboratory. Amy Yang has served as a consultant for Shire Therapeutics. Chunli Yu is an employee of Sema4, a for-profit genetic testing laboratory. The other authors declare no conflicts of interest.

Corresponding author

Correspondence to Melissa P. Wasserstein MD.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41436-018-0129-y

Further reading